Drug Trial Radar · NCT05217927
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
Last checked: Nov 19, 2026Latest source record: Dec 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,415
Actual
Start
Mar 4, 2022
Primary completion
Oct 22, 2024
Study completion Dec 11, 2024
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Feb 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
Conditions
- Migraine
Interventions
Rimegepant 75mg daily dosingDrug
Daily
Rimegepant 75mg every other day dosingDrug
Every other day
Placebo comparator dosingDrug
Placebo comparator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change From Observation Phase (OP) in the Number of Migraine Days Per Month Over Entire DBT Phase (Weeks 1 to 12)Time frame: Observation phase (from 31 days prior to randomization), DBT phase (through Month 3 [Week 1 to 12])
Locations
107 sites in 10 countries. Site status is shown where the registry gives one.
AMR Clinical
Tempe, Arizona
Axiom Research, Llc
Colton, California
Clinical Research Institute
Los Angeles, California
Wr-Pri, Llc
Newport Beach, California
California Neuroscience Research Medical Group, inc.
Sherman Oaks, California
Neurology Offices of South Florida, PLLC
Boca Raton, Florida
AppleMed Research Group, LLC
Miami, Florida
Clinical Investigation Specialists, Inc.
Gurnee, Illinois
MediSphere Medical Research Center, LLC
Evansville, Indiana
Collective Medical Research
Overland Park, Kansas
Clinvest Research, LLC
Springfield, Missouri
Alliance for Multispecialty Research, LLC
Las Vegas, Nevada
Dent Neurosciences Research Center, Inc.
Amherst, New York
Montefiore Medical Center
The Bronx, New York
Upstate Clinical Research Associates, LLC
Williamsville, New York
Wellnow Urgent Care and Research
Columbus, Ohio
Hometown Urgent Care and Research
Huber Heights, Ohio
Velocity Clinical Research, Medford
Medford, Oregon
Preferred Primary Care Physicians, Inc.
Pittsburgh, Pennsylvania
Velocity Clinical Research - Providence
East Greenwich, Rhode Island
Velocity Clinical Research - Columbia
Columbia, South Carolina
Velocity Clinical Research, Gaffney
Gaffney, South Carolina
Tribe Clinical Research LLC
Greenville, South Carolina
Clinical Research Associates, Inc.
Nashville, Tennessee
FutureSearch Trials of Neurology
Austin, Texas
FutureSearch Trials of Dallas, LP
Dallas, Texas
Texas Center for Drug Development, Inc.
Houston, Texas
APD Clinical Research
Magnolia, Texas
Wasatch Clinical Research , LLC(Administrative Location)
Salt Lake City, Utah
Seattle Clinical Research Center
Seattle, Washington
Christian-Doppler-Klinik
Salzburg, Austria
Medizinische Universitat Innsbruck
Innsbruck, Tyrol, Austria
Calgary Headache & Assessment Management Program (CHAMP)
Calgary, Alberta, Canada
OCT Research ULC
Kelowna, British Columbia, Canada
James K. Lai MD Inc.
Vancouver, British Columbia, Canada
Centricity Research
Halifax, Nova Scotia, Canada
Aggarwal and Associates Limited
Brampton, Ontario, Canada
Manna Research Inc. (Burlington North)
Burlington, Ontario, Canada
Milestone Research Inc.
London, Ontario, Canada
Bluewater Clinical Research Group Inc.
Sarnia, Ontario, Canada
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.